Navigation Links
Vermillion Sharpens Focus and Streamlines Operations in 2012
Date:1/4/2012

will place greater focus and priority on those activities that it can deliver upon and explore partnerships which can accelerate the development and commercialization of the oncology and cardiovascular programs."

About Vermillion

Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its well-known scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Additional information about Vermillion can be found at www.vermillion.com.

Forward-Looking Statement

Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, inclu
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Vermillion Receives Notice of Allowance for 5th Biomarker Patent Related to Peripheral Artery Disease
2. Vermillion Reports Results for the Second Quarter 2011
3. Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent
4. Vermillion Announces Joining Russell Microcap® Index
5. Vermillion Announces Notice of Allowance for Alzheimer Patent
6. Vermillion Announces the Appointment of Bruce Huebner to its Board of Directors
7. Vermillion to Host Conference Call to Present Company Update and Review Financial Results for the First Quarter 2011
8. Stephens Initiates Coverage on Vermillion
9. Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
10. Vermillion Announces Issuance of European Patent
11. Vermillion to Attend Society of Gynecologic Oncologists Meeting March 15-19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 The congress ... Transplant Association) is the biggest congress in ... Nearly 10,000 participants are in Istanbul ... research findings. New pioneering studies have been presented: ... PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ESA USE" ...
(Date:5/21/2013)... Savoury Systems International (SSI), a leader ... to Southeastern USA Sales Broker. Braddy’s new role will ... the Southeast. , In 2004 Braddy founded ... to food processors and industrial manufacturers. Braddy has ... industry and has over 25 years of sales management ...
(Date:5/21/2013)... 21, 2013 Clinverse, Inc. ... for clinical trials, announced today it has formed ... Clinverse’s ClinPay® FLS eClinical commerce platform aggregates ... SpendMD ™, Aggregate Spend Solutions’ recently-launched ... tracking and reporting transfer of value at investigator ...
(Date:5/21/2013)... 2013 Smarter Security, Inc., provider of ... announced that Genzyme, a Sanofi company and leading biotech ... CL for a multi-use facility in the United States. ... Genzyme buildings, this latest order underscores the satisfaction and ... detection device improving doorway access control. , ...
Breaking Biology Technology:ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3
... for Continued Long-Term Growth, Conference Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET), ... Q3 2008 ... 190.5% increase Naglazyme Net Product ... 56.3% increase Aldurazyme Net Sales by Genzyme ...
... NVAX ) a clinical-stage vaccine company, announced today that ... presenting at,the BIO Investor Forum 2008 at 8:30 am. ... San Francisco, California. Dr. Singhvi will provide an,overview of ... the live presentation can be accessed via the Company ...
... quarter (26%) of primary care patients 40 years of age ... had airflow ... - Percentages were greater with increasing patient age and smoking ... findings from a cross-sectional study which showed,that 26 percent of ...
Cached Biology Technology:BioMarin Announces Third Quarter 2008 Financial Results 2BioMarin Announces Third Quarter 2008 Financial Results 3BioMarin Announces Third Quarter 2008 Financial Results 4BioMarin Announces Third Quarter 2008 Financial Results 5BioMarin Announces Third Quarter 2008 Financial Results 6BioMarin Announces Third Quarter 2008 Financial Results 7BioMarin Announces Third Quarter 2008 Financial Results 8BioMarin Announces Third Quarter 2008 Financial Results 9BioMarin Announces Third Quarter 2008 Financial Results 10BioMarin Announces Third Quarter 2008 Financial Results 11BioMarin Announces Third Quarter 2008 Financial Results 12New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD 2New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD 3New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD 4
(Date:5/21/2013)... path of insulin action in cells in precise detail ... understanding what goes wrong in diabetes. , The ... James from Sydney,s Garvan Institute of Medical Research, is ... prestigious journal Cell Metabolism . , First discovered ... role in the body because it helps us lower ...
(Date:5/21/2013)... ANDOVER, Mass. , May 21, 2013 ... that CX50 xMATRIX, the world,s first portable ultrasound with ... Intracardiac Echo (ICE) capability. The CX50 xMATRIX with available ... Paris at the EuroPCR, official ... (EAPCI), May 21-24. Since its launch in ...
(Date:5/21/2013)... the way genes function without changing the underlying ... blood of pregnant women during any trimester, potentially ... the weeks after giving birth, and an opportunity ... findings of the small study involving 52 pregnant ... Molecular Psychiatry . , "Postpartum depression can be ...
Breaking Biology News(10 mins):Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3
... from the University of Leeds has identified how the virus which ... a possible new treatment for the disease. , Kaposi,s Sarcoma ... widespread in sub-Saharan Africa, where it is the most common cause ... Faculty of Biological Sciences found that a human protein known ...
... them locate the big catch. Now Tel Aviv University researchers ... help scientists accelerate their research into new fat-melting drugs. ... of the journal Tissue Engineering , fits onto a ... to measure a broad number of physical parameters in the ...
... (AML) is relatively rare in children, drinking alcohol during ... paper published in Cancer Epidemiology, Biomarkers & Prevention ... Research. Julie Ross, Ph.D., director of the division ... of Minnesota, said there are about 700 cases of ...
Cached Biology News:A 'fat forward' research tool 2
... InnoScan700 is a fluorescence scanner with ... biochip (Staggered/Orange Packing, Protein, CGH, ) spotted ... the range of InnoScan700 scanners include three ... InnoScan700A is a simultaneous dual fluorescence scanner ...
... DNAscope is an integrated confocal laser scanner ... integrated into your specific application. GeneFocus can ... tailor the system to your specifications. ... design has been modularized and built onto ...
... Hybridization chambers with forced convection Temperature range ... to 99.9 C / 212 F Patented ... results DS controller Timer 0 to ... accuracy of a tenth of a degree ...
... tubes provide a fast, easy to use, ... counting. They are 15 times faster and ... less than 5%). ,The VoluPAC tubes enable ... (PCV) in a cell suspension, resulting in ...
Biology Products: